Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date January 14, 2022 · Filed January 18, 2022
Section 16 reporting ended · disclosed 2022-01-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 264,324 |
Reported balance
Holding disclosure · report date 2022-01-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 264,324 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2021 Filed Oct 12, 2021 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 6,470 | $30.88 | $199,793.60 |
DisclosureSEC source: 0001219036-21-000031 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,324 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock October 8, 2021. Read SEC document |
| October 09, 2021 Filed Oct 12, 2021 20:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 4,341 | $30.88 | $134,050.08 |
DisclosureSEC source: 0001219036-21-000031 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,794 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on October 8, 2021. Read SEC document |
| September 26, 2021 Filed Sep 27, 2021 23:40 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 3,633 | $33.31 | $121,015.23 |
DisclosureSEC source: 0001219036-21-000029 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,135 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 25, 2021 Filed Sep 27, 2021 23:40 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 9,747 | $33.31 | $324,672.57 |
DisclosureSEC source: 0001219036-21-000029 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,768 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 23:40 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 200 | $35.06 | $7,012.00 |
DisclosureSEC source: 0001219036-21-000029 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,515 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 21:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 58,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001219036-21-000027 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,715 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 01:54 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 2,233 | $34.81 | $77,730.73 |
DisclosureSEC source: 0001219036-21-000025 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,317 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 25, 2021. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · derivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 30,000 | $35.57 | $1,067,100.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 24, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 30,000 | $27.07 | $812,100.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · derivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 40,000 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · derivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 10,000 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 40,000 | $35.07 | $1,402,800.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 40,000 | $27.07 | $1,082,800.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 10,000 | $35.57 | $355,700.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:32 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 10,000 | $27.07 | $270,700.00 |
DisclosureSEC source: 0001219036-21-000024 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 21:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 28,225 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000022 · edgardoc.xml · derivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 28,225 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 21:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 28,225 | $35.57 | $1,004,008.41 |
DisclosureSEC source: 0001219036-21-000022 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.57 to $35.60, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 21:47 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 28,225 | $27.07 | $764,050.75 |
DisclosureSEC source: 0001219036-21-000022 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,775 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 18 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,225 Underlying: Common Stock · 11,775 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 38,225 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 17 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 38,225 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 11,775 | $35.57 | $418,855.59 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 12 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.57 to $35.58, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 11,775 | $27.07 | $318,749.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 11 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 38,225 | $35.24 | $1,347,171.32 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 10 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.09 to $35.51, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 04, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 38,225 | $27.07 | $1,034,750.75 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,775 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 16 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,225 Underlying: Common Stock · 1,775 shares Expires 2022-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,225 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 15 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,225 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 14 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,830 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,170 | $0.00 Strike: $23.98 | $0.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · derivative · entry 13 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,170 shares Expires 2022-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 4,170 | $34.00 | $141,780.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 4,170 | $23.98 | $99,996.60 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 27,830 | $34.00 | $946,220.00 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 27,830 | $23.98 | $667,363.40 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 1,775 | $35.07 | $62,249.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 1,775 | $27.07 | $48,049.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 16,225 | $33.99 | $551,487.75 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 16,225 | $26.49 | $429,800.25 |
DisclosureSEC source: 0001219036-21-000020 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 12 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,225 Underlying: Common Stock · 40,000 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,295 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 11 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,225 Underlying: Common Stock · 3,295 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 40,000 | $33.74 | $1,349,756.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 8 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.49 to $33.96, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 40,000 | $26.49 | $1,059,600.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 7 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 3,295 | $33.69 | $111,011.52 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 6 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.205 to $33.95, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 13, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 3,295 | $26.49 | $87,284.55 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 5 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,295 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 10 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,520 Underlying: Common Stock · 13,295 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 36,705 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · derivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,815 Underlying: Common Stock · 36,705 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 13,295 | $33.55 | $446,075.17 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 4 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 13,295 | $26.49 | $352,184.55 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 3 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 36,705 | $33.55 | $1,231,430.73 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 2 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,550 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.01, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 21:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionCommon Stock | 36,705 | $26.49 | $972,315.45 |
DisclosureSEC source: 0001219036-21-000018 · edgardoc.xml · nonDerivative · entry 1 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 22:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,603 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001219036-21-000016 · edgardoc.xml · derivative · entry 9 LANCHBURY JERRY S · CIK 0001219036 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,520 Underlying: Common Stock · 5,603 shares Expires 2021-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.